Overview

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Status:
Completed
Trial end date:
2011-04-05
Target enrollment:
Participant gender:
Summary
This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.